SYS6090 + SYS6043 + bevacizumab

SYS6090 + SYS6043 + bevacizumab is an investigational combination regimen developed by CSPC Megalith Biopharmaceutical (a subsidiary of CSPC Pharmaceutical Group) for the treatment of advanced hepatocellular carcinoma (HCC). The regimen leverages three distinct therapeutic modalities: **SYS6090**, a recombinant humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor to enhance antitumor T-cell responses; **SYS6043**, an antibody-drug conjugate (ADC) targeting B7-H3 (CD276), which is overexpressed in various solid tumors, delivering a cytotoxic topoisomerase I inhibitor payload directly to tumor cells; and **bevacizumab**, a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) to suppress tumor angiogenesis. This triplet combination is currently being evaluated in Phase Ib/II clinical trials to assess its safety, tolerability, and efficacy, aiming to provide a synergistic therapeutic effect by combining immune checkpoint inhibition, targeted chemotherapy, and anti-angiogenic therapy.

Other names

SYS6090 Injection + SYS6043 Injection + bevacizumab